2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
76
Polycystic Ovary Syndrome
3
Neoplasms, Hormone-Dependent
3
Neoplasm Metastasis
3
Arthralgia
3
Advanced Breast Cancer
3
Osteoporosis
2
Fractures, Bone
2
Endometrial Neoplasms
2
Carcinoma, Lobular
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Ductal, Breast
2
Breast Diseases
2
Breast Cancer Female
2
Sexuality
1
Sexual Dysfunctions, Psychological
1
Neurotoxicity Syndromes
1
Luminal B/HER2-negative Breast Cancer
1
Leiomyoma
1
Infertility
1
Hot Flashes
1
Hormone-receptor-positive Breast Cancer
1
Hormone Receptor Positive Breast Carcinoma
1
Hormone Receptor Positive Advanced Breast Cancer
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HR+/HER2- Early Breast Cancer
1
HR+/HER2+ Early Breast Cancer
1
Fatigue
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Stromal Tumors
1
Interventions
Fulvestrant
6
Letrozole
4
Capecitabine
4
exemestane
3
dalpiciclib
3
Trastuzumab
3
Docetaxel
3
Anastrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
nirogacestat
1
margetuximab
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Tamoxifen
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Cancer Metastatic
×
Aromatase Inhibitors
×
Clear all
NCT02511639
2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3
Completed
110 enrolled